WINDLASBSEWindlas Biotech LtdMediumNeutral
Announced Mon, 29 Jun · 16:24 IST

Windlas Biotech gets ICRA rating upgrade on short-term facilities

Rating UpgradedCredit & Debt View source PDF

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.3%1-day move
₹860.55
prior close
₹859.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.1+0.5+0.4+0.3-0.3+1.6-0.1-0.4-3.7+2.4
Up moveDown movePending
AI summary

ICRA reaffirmed Windlas Biotech's long-term rating at A+ (Stable) and upgraded its short-term rating from A+ to A1+ on working capital facilities worth Rs 84.90 crore. The facilities are spread across HSBC (Rs 40.10 cr), HDFC Bank (Rs 23.30 cr), and IndusInd Bank (Rs 21.50 cr). Review date: June 19, 2026.

Likely market impact

Positive signal on financial health. A1+ is ICRA's highest short-term rating, indicating strong ability to meet short-term obligations and lower borrowing costs.